SA518390907B1 - إنشاء متواليات لجزيء مفرد لحمض ريبوزي نووي منزوع الأكسجين في البلازما - Google Patents
إنشاء متواليات لجزيء مفرد لحمض ريبوزي نووي منزوع الأكسجين في البلازما Download PDFInfo
- Publication number
- SA518390907B1 SA518390907B1 SA518390907A SA518390907A SA518390907B1 SA 518390907 B1 SA518390907 B1 SA 518390907B1 SA 518390907 A SA518390907 A SA 518390907A SA 518390907 A SA518390907 A SA 518390907A SA 518390907 B1 SA518390907 B1 SA 518390907B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- deoxyribonucleic acid
- concatemer
- sequences
- sequence
- dna
- Prior art date
Links
- 108020004414 DNA Proteins 0.000 title claims abstract description 335
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 77
- 102000053602 DNA Human genes 0.000 title claims description 82
- 239000012634 fragment Substances 0.000 claims abstract description 299
- 238000000034 method Methods 0.000 claims abstract description 162
- 108091028732 Concatemer Proteins 0.000 claims abstract description 156
- 210000000349 chromosome Anatomy 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 34
- 238000001514 detection method Methods 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 240000000233 Melia azedarach Species 0.000 claims 2
- 241000270299 Boa Species 0.000 claims 1
- 101100086716 Caenorhabditis elegans ran-3 gene Proteins 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 claims 1
- 101100119135 Mus musculus Esrrb gene Proteins 0.000 claims 1
- 241000772415 Neovison vison Species 0.000 claims 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 claims 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 101150029150 syd-1 gene Proteins 0.000 claims 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 abstract description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 13
- 210000003754 fetus Anatomy 0.000 description 35
- 238000009826 distribution Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 27
- 125000006850 spacer group Chemical group 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 22
- 238000007672 fourth generation sequencing Methods 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 16
- 230000002759 chromosomal effect Effects 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 230000004075 alteration Effects 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
- 230000001605 fetal effect Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000011987 methylation Effects 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108020004566 Transfer RNA Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000001712 DNA sequencing Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000009598 prenatal testing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 210000001766 X chromosome Anatomy 0.000 description 3
- 208000036878 aneuploidy Diseases 0.000 description 3
- 231100001075 aneuploidy Toxicity 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000003350 DNA copy number gain Effects 0.000 description 2
- 230000004536 DNA copy number loss Effects 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001369 bisulfite sequencing Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000003793 prenatal diagnosis Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000003765 sex chromosome Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- MJEQLGCFPLHMNV-UHFFFAOYSA-N 4-amino-1-(hydroxymethyl)pyrimidin-2-one Chemical compound NC=1C=CN(CO)C(=O)N=1 MJEQLGCFPLHMNV-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 244000198134 Agave sisalana Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- 241000948258 Gila Species 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229920006068 Minlon® Polymers 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 101150107869 Sarg gene Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010020488 hydrocele Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- -1 hydroxylmethyl Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000030454 monosomy Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/151—Modifications characterised by repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/146—Concentration of target or template
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/631—Detection means characterised by use of a special device being a biochannel or pore
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204396P | 2015-08-12 | 2015-08-12 | |
| PCT/CN2016/094802 WO2017025059A1 (en) | 2015-08-12 | 2016-08-12 | Single-molecule sequencing of plasma dna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA518390907B1 true SA518390907B1 (ar) | 2021-09-08 |
Family
ID=57983895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA518390907A SA518390907B1 (ar) | 2015-08-12 | 2018-02-12 | إنشاء متواليات لجزيء مفرد لحمض ريبوزي نووي منزوع الأكسجين في البلازما |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11319586B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3334843A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6867045B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115433769A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2016305103C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2995422A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1248286A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL285795B (cg-RX-API-DMAC7.html) |
| MY (1) | MY188348A (cg-RX-API-DMAC7.html) |
| SA (1) | SA518390907B1 (cg-RX-API-DMAC7.html) |
| TW (2) | TWI793586B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017025059A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111356772B (zh) | 2017-08-23 | 2023-10-03 | 豪夫迈·罗氏有限公司 | 酶筛选方法 |
| WO2019051244A1 (en) * | 2017-09-07 | 2019-03-14 | Coopersurgical, Inc. | SYSTEMS AND METHODS FOR NON-EFFRACTIVE PREIMPLANTATORY GENETIC DIAGNOSIS |
| WO2019084158A1 (en) | 2017-10-26 | 2019-05-02 | Ultima Genomics, Inc. | METHODS AND SYSTEMS FOR SEQUENCE CALL |
| EP3731959B1 (en) | 2017-12-29 | 2025-10-08 | Clear Labs, Inc. | Automated priming and library loading device |
| US12378603B2 (en) | 2018-04-20 | 2025-08-05 | The Regents Of The University Of California | Nucleic acid sequencing methods and computer-readable media for practicing same |
| EP3939047B1 (en) | 2019-03-10 | 2025-09-17 | Ultima Genomics, Inc. | Methods and systems for sequence calling |
| EP3987525A1 (en) | 2019-06-21 | 2022-04-27 | CooperSurgical, Inc. | System and method for determining genetic relationships between a sperm provider, oocyte provider, and the respective conceptus |
| US20220411863A1 (en) * | 2019-11-25 | 2022-12-29 | William Marsh Rice University | Linear dna assembly for nanopore sequencing |
| WO2022008641A1 (en) | 2020-07-08 | 2022-01-13 | Roche Sequencing Solutions, Inc. | Split-pool synthesis apparatus and methods of performing split-pool synthesis |
| JP2023545478A (ja) | 2020-10-15 | 2023-10-30 | カパ バイオシステムズ，インコーポレイティド | 次世代配列決定ライブラリ調製のための電気泳動デバイスおよび方法 |
| CN114507708A (zh) * | 2020-11-16 | 2022-05-17 | 唐纳德·李 | 一种制备长分子测序dna的方法 |
| EP4308723B1 (en) | 2021-03-15 | 2025-04-23 | F. Hoffmann-La Roche AG | Targeted next-generation sequencing via anchored primer extension |
| JP7657961B2 (ja) | 2021-03-26 | 2025-04-07 | エフ． ホフマン－ラ ロシュ アーゲー | ハイブリダイゼーション緩衝調合物 |
| EP4314337A1 (en) | 2021-04-01 | 2024-02-07 | F. Hoffmann-La Roche AG | Immune cell counting of sars-cov-2 patients based on immune repertoire sequencing |
| CN117545855A (zh) * | 2021-04-12 | 2024-02-09 | 香港中文大学 | 使用电信号的碱基修饰分析 |
| WO2023023561A1 (en) * | 2021-08-17 | 2023-02-23 | Quantapore, Inc. | Multiplex binding assays with optical nanopore readout |
| US20250243536A1 (en) * | 2021-10-18 | 2025-07-31 | Belgian Volition Srl | Use of nanopore sequencing for determining the origin of circulating dna |
| US20250368983A1 (en) | 2022-06-30 | 2025-12-04 | Kapa Biosystems, Inc. | Controlling for tagmentation sequencing library insert size using archaeal histone-like proteins |
| CN114898802B (zh) * | 2022-07-14 | 2022-09-30 | 臻和(北京)生物科技有限公司 | 基于血浆游离dna甲基化测序数据的末端序列频率分布特征确定方法、评价方法及装置 |
| CN119895049A (zh) | 2022-09-02 | 2025-04-25 | 豪夫迈·罗氏有限公司 | 对下一代靶标富集性能的改进 |
| WO2024215528A1 (en) | 2023-04-13 | 2024-10-17 | Ventana Medical Systems, Inc. | Proliferation assay for fixed solid tumors |
| WO2024256358A2 (en) | 2023-06-14 | 2024-12-19 | F. Hoffmann-La Roche Ag | Accelerated marking of 5-formyl cytosine and use in nucleic acid methylation sequencing |
| WO2025193604A1 (en) | 2024-03-11 | 2025-09-18 | Ventana Medical Systems, Inc. | Non-enzymatic dissociation of ffpe tissue and generation of single cells with intact cell surface markers |
| WO2025210056A1 (en) | 2024-04-03 | 2025-10-09 | Roche Sequencing Solutions, Inc. | In vitro amplification of dna methylation patterns |
| WO2025247632A1 (en) | 2024-05-27 | 2025-12-04 | European Molecular Biology Laboratory | Preparation of cell-free fragmented nucleic acids for genetic analysis sequencing |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020197618A1 (en) | 2001-01-20 | 2002-12-26 | Sampson Jeffrey R. | Synthesis and amplification of unstructured nucleic acids for rapid sequencing |
| GB0504774D0 (en) * | 2005-03-08 | 2005-04-13 | Lingvitae As | Method |
| JP2008161056A (ja) * | 2005-04-08 | 2008-07-17 | Hiroaki Mita | Ｄｎａ配列解析装置、ｄｎａ配列解析方法およびプログラム |
| KR102561664B1 (ko) | 2007-07-23 | 2023-07-28 | 더 차이니즈 유니버시티 오브 홍콩 | 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의 진단 방법 |
| US9175341B2 (en) | 2008-12-11 | 2015-11-03 | Pacific Biosciences Of California, Inc. | Methods for identifying nucleic acid modifications |
| DE102008061772A1 (de) * | 2008-12-11 | 2010-06-17 | Febit Holding Gmbh | Verfahren zur Untersuchung von Nukleinsäure-Populationen |
| LT3783110T (lt) | 2009-11-05 | 2023-01-25 | The Chinese University Of Hong Kong | Vaisiaus genomo analizė iš motinos biologinio mėginio |
| US8620593B2 (en) | 2009-11-06 | 2013-12-31 | The Chinese University Of Hong Kong | Size-based genomic analysis |
| US9121823B2 (en) * | 2010-02-19 | 2015-09-01 | The Trustees Of The University Of Pennsylvania | High-resolution analysis devices and related methods |
| KR20120045922A (ko) * | 2010-11-01 | 2012-05-09 | 엘지전자 주식회사 | 나노 포어를 포함하는 염기 서열 결정 장치 |
| EP2646579B1 (en) | 2010-11-30 | 2017-06-14 | The Chinese University Of Hong Kong | Detection of genetic or molecular aberrations associated with cancer |
| CA2843136C (en) * | 2011-07-25 | 2020-12-29 | Oxford Nanopore Technologies Limited | Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores |
| KR101974492B1 (ko) * | 2011-07-26 | 2019-05-02 | 베리나타 헬스, 인코포레이티드 | 샘플 중 상이한 이수성의 존재 또는 부재를 결정하는 방법 |
| US20130040827A1 (en) * | 2011-08-14 | 2013-02-14 | Stephen C. Macevicz | Method and compositions for detecting and sequencing nucleic acids |
| CA2861457A1 (en) | 2012-01-20 | 2013-07-25 | Genia Technologies, Inc. | Nanopore based molecular detection and sequencing |
| US9116118B2 (en) | 2012-06-08 | 2015-08-25 | Pacific Biosciences Of California, Inc. | Modified base detection with nanopore sequencing |
| WO2013188841A1 (en) * | 2012-06-15 | 2013-12-19 | Genia Technologies, Inc. | Chip set-up and high-accuracy nucleic acid sequencing |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| GB201215449D0 (en) * | 2012-08-30 | 2012-10-17 | Zoragen Biotechnologies Llp | Method of detecting chromosonal abnormalities |
| EP2898100B9 (en) | 2012-09-20 | 2023-08-02 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| EP3495506B1 (en) * | 2013-12-11 | 2023-07-12 | AccuraGen Holdings Limited | Methods for detecting rare sequence variants |
| DK3218519T3 (da) * | 2014-11-11 | 2020-12-21 | Bgi Shenzhen | Multipass-sekvensering |
| WO2017195391A1 (ja) | 2016-05-10 | 2017-11-16 | 日本電気株式会社 | 需給調整システム、制御装置、制御方法、およびプログラム |
-
2016
- 2016-08-12 MY MYPI2018000139A patent/MY188348A/en unknown
- 2016-08-12 EP EP16834683.1A patent/EP3334843A4/en active Pending
- 2016-08-12 JP JP2018506601A patent/JP6867045B2/ja active Active
- 2016-08-12 HK HK18108082.2A patent/HK1248286A1/zh unknown
- 2016-08-12 CA CA2995422A patent/CA2995422A1/en active Pending
- 2016-08-12 WO PCT/CN2016/094802 patent/WO2017025059A1/en not_active Ceased
- 2016-08-12 CN CN202211147693.8A patent/CN115433769A/zh active Pending
- 2016-08-12 TW TW110115619A patent/TWI793586B/zh active
- 2016-08-12 US US15/235,630 patent/US11319586B2/en active Active
- 2016-08-12 TW TW105125873A patent/TWI728994B/zh active
- 2016-08-12 CN CN201680046621.0A patent/CN107849607B/zh active Active
- 2016-08-12 IL IL285795A patent/IL285795B/en unknown
- 2016-08-12 AU AU2016305103A patent/AU2016305103C1/en active Active
-
2018
- 2018-01-22 IL IL257074A patent/IL257074B/en unknown
- 2018-02-12 SA SA518390907A patent/SA518390907B1/ar unknown
-
2020
- 2020-03-26 AU AU2020202153A patent/AU2020202153B2/en active Active
-
2021
- 2021-03-31 JP JP2021060027A patent/JP7506408B2/ja active Active
-
2022
- 2022-03-18 US US17/698,574 patent/US20220205038A1/en active Pending
- 2022-06-22 IL IL294192A patent/IL294192B2/en unknown
-
2023
- 2023-04-27 AU AU2023202572A patent/AU2023202572B2/en active Active
-
2024
- 2024-06-07 JP JP2024092950A patent/JP2024113130A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518390907B1 (ar) | إنشاء متواليات لجزيء مفرد لحمض ريبوزي نووي منزوع الأكسجين في البلازما | |
| JP6680680B2 (ja) | 染色体変化の非侵襲性評価のための方法およびプロセス | |
| US20170240972A1 (en) | Methods and applications of gene fusion detection in cell-free dna analysis | |
| CN114072527B (zh) | 确定循环核酸的线性和环状形式 | |
| US20170058332A1 (en) | Identification of somatic mutations versus germline variants for cell-free dna variant calling applications | |
| TW201833329A (zh) | 腫瘤檢測之方法及系統 | |
| EP3288455A1 (en) | Diagnostic methods | |
| CN108026572A (zh) | 游离dna的片段化模式的分析 | |
| JP2015521028A (ja) | 標的大規模並列配列決定法を使用した対立遺伝子比分析による胎児トリソミーの非侵襲的出生前診断 | |
| CN107208153A (zh) | 血浆线粒体dna分析的应用 | |
| JP2023531720A (ja) | 核酸を解析するための方法および組成物 | |
| HK40083172A (en) | Single-molecule sequencing of plasma dna | |
| WO2025221865A1 (en) | Methods and compositions for cell free rna modification analysis | |
| HK40035887A (en) | Methods and processes for non-invasive assessment of chromosome alterations | |
| HK1245850B (en) | Single-molecule sequencing of plasma dna |